Navigation Links
Coherus Announces Initiation Of Phase 3 Trial Of CHS-0214 (Investigational Etanercept Biosimilar) In Chronic Plaque Psoriasis (RaPsOdy)
Date:7/16/2014

REDWOOD CITY, Calif., July 16, 2014 /PRNewswire/ -- Coherus BioSciences, Inc. announced the start of its Phase 3 trial of CHS-0214, a proposed biosimilar of etanercept  (Enbrel®), in chronic plaque psoriasis (the RaPsOdy trial).  This announcement follows the recent initiation of a Phase 3 trial of CHS-0214 in rheumatoid arthritis.  The Phase 3 psoriasis trial is a 48-week, randomized, double-blind, active-control, parallel-group, multicenter, global study in subjects with active, chronic plaque psoriasis who are naïve to systemic biologic therapy.  The study will seek to demonstrate biosimilarity between CHS-0214 and Enbrel® in terms of efficacy, safety and immunogenicity.  The primary efficacy endpoint is based on percent improvement in the Psoriasis Area and Severity Index (PASI) at 12 weeks.

"The initiation of the Phase 3 RaPsOdy trial is an important step toward our goal of increasing access to biosimilar etanercept for patients worldwide," said Barbara Finck, M.D., Chief Medical Officer of Coherus.  "It represents a pivotal study in the global clinical development for CHS-0214 and, if positive, will provide support for our marketing applications in Europe, the United States, and a number of other countries."

"Based on our evaluation of the analytical, nonclinical and clinical pharmacokinetic similarity of this molecule, we believe that this molecule has met our rigorous internal criteria for initiating our second Phase 3 trial in 2014," said Denny Lanfear, Coherus Chief Executive Officer.  "In concert with our partner Baxter, we are pleased to advance this product into late-stage development."

"With two late-stage trials now underway in partnership with Coherus, we are advancing our col
'/>"/>

SOURCE Coherus BioSciences, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Coherus Announces CHS-0214 (Proposed Etanercept Biosimilar) Meets Primary Endpoint In Pivotal Pharmacokinetic Clinical Study
2. Coherus anuncia que CHS-0214 (biosimilar etanercept propuesto) supera punto final primario en decisivo estudio clínico farmacocinético
3. Coherus Biosciences als Präsentator zur J.P. Morgan Annual Healthcare Conference 2014 eingeladen
4. Coherus Biosciences Invited to Present at 2014 J.P. Morgan Annual Healthcare Conference
5. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
6. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
7. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
8. Misonix Announces New Distribution Agreement For Panama
9. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
10. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
11. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... BRUSSELS , Sept. 1, 2015 ... (Euronext Brussels: UCB) today announced top-line results from ... Compared with Teriparatide in postmenopaUsal women with osteoporosis ... bisphosphonatE therapy). The study (NCT01796301) met the primary ... of romosozumab in the percent change of total ...
(Date:9/1/2015)... Konica Minolta Medical Imaging announced today the ... to deliver enterprise level imaging to community hospitals, clinics ... as the Konica Minolta AeroDR wireless flat panel detector, ... CR to DR. The SIGMA II CS-7s CR system ... unparalleled reliability and high capacity to help maximize patient ...
(Date:9/1/2015)... DALLAS , Sept. 1, 2015 UT ... and distinguished faculty members joined U.S. Representatives ... in a roundtable discussion on the 21 st ... biomedical research currently being considered by the ... faculty – including National Academy of Sciences members, department ...
Breaking Medicine Technology:Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 2Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 3Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 4Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 5Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 6Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 7Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 8Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 9Konica Minolta Launches New CR System with Low-Cost Upgrade Path to DR 2U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 2U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 3U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 4U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 5
... MacroChem Corporation (OTC,Bulletin Board: MACM) today announced results ... who completed a 48-week, U.S. multi-center,open-label efficacy and ... the treatment of onychomycosis (nail fungus). The composite,primary ... defined as,negative mycology (negative fungal culture and negative ...
... Sound Pharmaceuticals (SPI) has filed,an Investigational New ... of a proprietary formulation of ebselen for the ... oral capsule,containing ebselen, SPI-3005, will be tested in ... patients receiving platinum based chemotherapy.,This marks the second ...
Cached Medicine Technology:MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis 2MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis 3MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis 4MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis 5Sound Pharmaceuticals Files Second IND with the FDA for the Prevention of Chemotherapy Induced Hearing Loss in Advanced Stage Cancer 2
(Date:9/2/2015)... ... September 02, 2015 , ... Ovarian cancer continues to be the ... of getting ovarian cancer in her lifetime is approximately 1 in 75. This year ... cancer, and 14,000 will die. , There is no test to detect ovarian ...
(Date:9/2/2015)... ... September 02, 2015 , ... Lakeview Health, a ... to International Overdose Awareness Day. The goal is to provide people information regarding ... so that they may get help. , Lakeview Health will be ...
(Date:9/2/2015)... ... September 02, 2015 , ... Available ... marine cosmetics introduces PIONNIÈRE XMF Perfection Youth Rich Cream , an evolution ... biotechnological anti-aging power with a lipid-replenishing marine oil for intense nourishing and moisturizing. ...
(Date:9/2/2015)... ... 2015 , ... Please join the world renowned Brain Aneurysm ... established by the Foundation in 2007 with the help of Massachusetts State Representative ... remains our top priority,” commented Christine Buckley, Executive Director of the Brain Aneurysm ...
(Date:9/2/2015)... ... September 02, 2015 , ... Canopy Partners, a ... to the Inc. 5000 List, an independent ranking of the fastest- growing ... years, and this achievement puts Canopy in rarefied company. Over the years, this ...
Breaking Medicine News(10 mins):Health News:National Ovarian Cancer Coalition's DFW Chapter Features First Annual Teal Lights Display This Friday, September 4th, "National Wear Teal Day" 2Health News:National Ovarian Cancer Coalition's DFW Chapter Features First Annual Teal Lights Display This Friday, September 4th, "National Wear Teal Day" 3Health News:August 31 is International Overdose Awareness Day – Lakeview Health to Help Bring Awareness 2Health News:Phytomer announces PIONNIÈRE XMF Perfection Youth Rich Cream 2Health News:Phytomer announces PIONNIÈRE XMF Perfection Youth Rich Cream 3Health News:Phytomer announces PIONNIÈRE XMF Perfection Youth Rich Cream 4Health News:September Celebrated as Brain Aneurysm Awareness Month 2Health News:Canopy Partners Named to 2015 Inc. 5000 Fastest Growing Companies List 2
... can do well with stress busters. According to a world ... Taiwan on top of the list. China, the Philippines,// Botswana, ... their ranks on the “Stressed Out” Statistics. ,Businessmen ... 7000 businessmen from 30 countries were observed , amongst them ...
... Yoga guru Ramdev signed agreements with the Jharkhand government to ... of herbal plants.// ,The memorandums of understanding were signed ... ,Announcing government aid of Rs.10 million for the ... Jharkhand as a herbal state that can benefit the common ...
... University researcher Chensheng "Alex" Lu, PhD, 'Organic diets lower ... U.S. agricultural production.'// ,The fact is ... items. The result was that concentration of pesticides was ... by Dr. Lu, "The use of organophosphorus pesticides in ...
... to you readers but if new research is to be believed ... ,This revelation comes from American scientists who found that the ... by way of an increase the number of nerve connections in ... ,The Yale University is credited with the study and it ...
... Epidemiology Unit Director Dr Nihal Abeysinghe said that the country ... This is due to the result of the confirmation of ... are requesting the public to avoid importing poultry products from ... not contained by the Indian authorities then there is an ...
... of anabolic steroids, more specifically anabolic androgen steroid (AAS) ... sebaceous glands. Sebaceous glands present in the skin // ... of the body surface. ,Anabolic steroids are ... to treat unwanted weight loss in patients with HIV. ...
Cached Medicine News:Health News:Bird flu affects the export of poultry products to Sri Lanka and Nepal 2
Pipetman F is a fixed-volume, air-displacement pipette. Thirteen robust models cover a large volume range from 2 L to 1000 L, with Gilsons legendary accuracy and precision....
... Pipette is a synonym for pipetting accuracy, ... design, and superior operating comfort. Its single, ... measuring stroke and blow-out as well as ... ensures utmost accuracy and precision. Ejection sleeve ...
... Reference Series 2000 Pipette is a synonym ... compact and robust design, and superior operating ... to operate the measuring stroke and blow-out ... features:Eppendorf "pipette/tip" system ensures utmost accuracy and ...
... pipette is ideal for repeated ... Fixed volume FInnpipettes offer the ... other Finnpipette Digital pipettes: ... (1-40ul), Soft-touch tip ejection, Safety ...
Medicine Products: